Baseline characteristics of ETP-ALL/LBL patients
| Categories . | ||||
|---|---|---|---|---|
| . | Total . | ETP ALL . | Non-ETP ALL . | P value . |
| n . | 111 . | 19 . | 92 . | . |
| Diagnosis | ||||
| ALL | 76 (68) | 15 (79) | 61 (66) | |
| LBL | 35 (32) | 4 (21) | 31 (34) | .28 |
| Age | 30 (13-79) | 37 (19-75) | 30 (13-79) | .26 |
| Gender | ||||
| Female | 29 (26) | 4 (21) | 25 (27) | |
| Male | 82 (74) | 15 (79) | 67 (73) | .6 |
| Cytogenetics (n = 105) | ||||
| Diploid | 71 (68) | 7 (37) | 64 (75) | .002* |
| Hyperdiploid | 5 (5) | 2 (11) | 3 (3) | |
| Hypodiploid | 2 (2) | 2 (2) | ||
| Miscellaneous | 27 (25) | 10 (52) | 17 (20) | |
| Presenting laboratory values | ||||
| WBC (×109/L) | 8.0 (0.4-292.3) | 13.4 (0.8-87.4) | 7.8 (0.4-292.3) | .72 |
| WBC ≥100 (×109/L) | 8 (7) | 0 | 8 (9) | .18 |
| Platelet count (×109/L) | 127 (10-488) | 110 (10-391) | 150 (10-488) | .27 |
| Hemoglobin (g/dL) | 11.4 (6.8-16.7) | 10.3 (6.8-15) | 11.4 (7.2-16.7) | .15 |
| LDH (IU/L) | 938 (209-32 029) | 850 (209-4675) | 959 (236-32 029) | .2 |
| CNS involvement at diagnosis | 6 (5) | 3 (16) | 3 (3) | .03 |
| Treatment received | ||||
| Hyper-CVAD | 43 (39) | 6 (31) | 37 (40) | |
| Hyper-CVAD + nelarabine | 44 (40) | 9 (48) | 35 (38) | |
| Augmented BFM | 24 (21) | 4 (21) | 20 (22) | |
| Categories . | ||||
|---|---|---|---|---|
| . | Total . | ETP ALL . | Non-ETP ALL . | P value . |
| n . | 111 . | 19 . | 92 . | . |
| Diagnosis | ||||
| ALL | 76 (68) | 15 (79) | 61 (66) | |
| LBL | 35 (32) | 4 (21) | 31 (34) | .28 |
| Age | 30 (13-79) | 37 (19-75) | 30 (13-79) | .26 |
| Gender | ||||
| Female | 29 (26) | 4 (21) | 25 (27) | |
| Male | 82 (74) | 15 (79) | 67 (73) | .6 |
| Cytogenetics (n = 105) | ||||
| Diploid | 71 (68) | 7 (37) | 64 (75) | .002* |
| Hyperdiploid | 5 (5) | 2 (11) | 3 (3) | |
| Hypodiploid | 2 (2) | 2 (2) | ||
| Miscellaneous | 27 (25) | 10 (52) | 17 (20) | |
| Presenting laboratory values | ||||
| WBC (×109/L) | 8.0 (0.4-292.3) | 13.4 (0.8-87.4) | 7.8 (0.4-292.3) | .72 |
| WBC ≥100 (×109/L) | 8 (7) | 0 | 8 (9) | .18 |
| Platelet count (×109/L) | 127 (10-488) | 110 (10-391) | 150 (10-488) | .27 |
| Hemoglobin (g/dL) | 11.4 (6.8-16.7) | 10.3 (6.8-15) | 11.4 (7.2-16.7) | .15 |
| LDH (IU/L) | 938 (209-32 029) | 850 (209-4675) | 959 (236-32 029) | .2 |
| CNS involvement at diagnosis | 6 (5) | 3 (16) | 3 (3) | .03 |
| Treatment received | ||||
| Hyper-CVAD | 43 (39) | 6 (31) | 37 (40) | |
| Hyper-CVAD + nelarabine | 44 (40) | 9 (48) | 35 (38) | |
| Augmented BFM | 24 (21) | 4 (21) | 20 (22) | |
Cytogenetics either not done or insufficient metaphases recovered for 6 patients.
Diploid vs other.